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Abstract: OBJECTIVE: This study aimed to determine the benefits of sclerotherapy with OK-432 for
the treatment of postoperative chronic lymphocele. BACKGROUND: Postoperative chronic lymphocele
formation is common and accounts for a high postoperative morbidity. Nonsurgical strategies comprise
repetitive percutaneous fluid aspiration or percutaneous sclerotherapy. OK-432 has been used to treat
congenital lymphatic malformations with several reports of promising results. We hypothesized that
it is more beneficial than repetitive percutaneous fluid aspiration for the treatment of symptomatic
lymphocele. METHODS: Two cohorts of melanoma patients who developed recurrent lymphocele after
lymph node dissection from January 2013 to August 2017 were compared. The first cohort was treated
with repetitive percutaneous fluid aspiration (n = 20). The second cohort received OK-432 sclerotherapy
(n = 20). Primary end points were overall treatment duration, number of treatment sessions, and the
clinical success in both cohorts. Secondary end points were surgical site infection rate, need for additional
antibiotic treatment, wound healing disorders, and the need for revision surgery. RESULTS: Mean overall
duration of treatment with sclerotherapy was significantly shorter than with repetitive aspiration (9.4
± 7.2 vs 47.5 ± 31.9 days, P < 0.01). Mean number of sclerotherapy treatment sessions were 2.5 ±
1.2. Clinical success with OK-432 was 19 of 20, and that with repeated aspiration was 7 of 20 (฀ =
15.82, P < 0.001). No surgical site infection occurred in the sclerotherapy cohort, which was significantly
lower than those treated with repetitive aspiration (P < 0.03). Surgical revision was mandatory in 12 of
20 patients who were treated with repetitive aspiration, and only 1 of 20 patients in the sclerotherapy
cohort. CONCLUSION: Sclerotherapy with OK-432 for the treatment of postoperative lymphocele is
highly beneficial with a significant reduction of morbidity and the overall treatment time compared with
repetitive aspiration.
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Sclerotherapy With OK-432 for the Treatment of Symptomatic
Lymphocele After Lymph Node Dissection
A Retrospective Comparative Cohort Study
Semra Uyulmaz, MD,a Gilbert Puippe, MD,b Nilgün Büyükakyüz, MD,a Pietro Giovanoli, MD,a
Thomas Pfammatter, MD,b and Nicole Lindenblatt, MDa
Objective: This study aimed to determine the benefits of sclerotherapy with
OK-432 for the treatment of postoperative chronic lymphocele.
Background: Postoperative chronic lymphocele formation is common and ac-
counts for a high postoperative morbidity. Nonsurgical strategies comprise repet-
itive percutaneous fluid aspiration or percutaneous sclerotherapy. OK-432 has
been used to treat congenital lymphatic malformations with several reports of
promising results. We hypothesized that it is more beneficial than repetitive per-
cutaneous fluid aspiration for the treatment of symptomatic lymphocele.
Methods: Two cohorts of melanoma patients who developed recurrent
lymphocele after lymph node dissection from January 2013 to August 2017 were
compared. The first cohort was treated with repetitive percutaneous fluid aspiration
(n = 20). The second cohort received OK-432 sclerotherapy (n = 20). Primary end
points were overall treatment duration, number of treatment sessions, and the clin-
ical success in both cohorts. Secondary end points were surgical site infection rate,
need for additional antibiotic treatment, wound healing disorders, and the need for
revision surgery.
Results:Mean overall duration of treatment with sclerotherapy was significantly
shorter than with repetitive aspiration (9.4 ± 7.2 vs 47.5 ± 31.9 days, P < 0.01).
Mean number of sclerotherapy treatment sessions were 2.5 ± 1.2. Clinical success
with OK-432 was 19 of 20, and that with repeated aspiration was 7 of 20
(χ2 = 15.82, P < 0.001). No surgical site infection occurred in the sclerotherapy
cohort, which was significantly lower than those treated with repetitive aspiration
(P < 0.03). Surgical revisionwasmandatory in 12 of 20 patients whowere treated
with repetitive aspiration, and only 1 of 20 patients in the sclerotherapy cohort.
Conclusion: Sclerotherapy with OK-432 for the treatment of postoperative
lymphocele is highly beneficial with a significant reduction of morbidity and
the overall treatment time compared with repetitive aspiration.
Key Words: lymphocele, sclerotherapy, lymph fistula, therapy,
lymph node dissection
(Ann Plast Surg 2020;00: 00–00)
A chronic fluid accumulation after lymph node dissection is derivedfrom severed afferent lymphatic vessels at the site where tissue has
been removed and is referred to as a lymphocele.1,2 Symptomatic
lymphocele formation (LF) may occur after lymphadenectomy for var-
ious malignant tumors, with a reported incidence ranging from 40% to
50%.3 Its incidence after lymph node biopsy is less than 7%.4 It may
cause a palpable swelling with regional discomfort or pain. Consequent
tension on skin sutures may hamper primary wound healing. This may
lead to prolonged in-hospital stay and/or multiple outpatient visits with
increasing costs. Despite improved recognition of risk factors, such as
high body mass index, dead space formation after surgery and early re-
moval or insufficient suction of drains LF remains a common problem.5,6
Predictive factors are the amount of tissue excised, for example, level of
lymph node dissection, radiation at the operating site, or systemic adju-
vant chemotherapy before surgery. Muscle flaps are efficient in reducing
dead space and postoperative chronic fluid accumulation primarily in se-
lective high-risk patients and in revision surgery.7 The use of fibrin seal-
ants has been suggested to prevent LF, but a meta-analysis found that
until now trials have been too small and methodology has been poor.8
A combination of capsule excision and selective lymph vessel ligation
with nonabsorbable sutures and titanium clips may increase the clinical
success.9,10 However, when there is a high lymphatic upload through a
main pathway producing high pressure, simple ligation might come off
or fail. Reconstructive lymphatic microsurgery is a new promising ap-
proach but not readily performed by all reconstructive surgeons.
Nonsurgical therapeutical strategies comprise repetitive percuta-
neous fluid aspiration (RA) or percutaneous sclerotherapy (ST) using dif-
ferent agents (eg, ethanol, polyvidone-iodine, or tetracycline). The basic
mechanism of action of ST is that the lymphocele is filled with an agent,
which chemically irritates the surrounding tissue and induces an inflam-
matory reaction. The inflammatory process leads to a fibrotic response
that enables to seal the dead space, which is a reservoir for fluid accumu-
lation. Available studies about frequently used sclerosing agents such as
ethanolum absolutum, tetracycline, and povidone iodine are small scale
and lack standardized procedures without proving superiority.
OK-432 (Picibanil; Chugai Pharmaceutical Co Ltd, Tokyo,
Japan) was developed in 1967 by Okamoto H. initially as an anticancer
agent for malignant pleural effusion (Chemical Abstract Services Num-
ber: 39325-01-4). Meanwhile, it has gained popularity among interven-
tional radiologist owing to its sclerosing effect.11 Pharmaceutically
OK-432 is a special preparation of the low-virulent strain “Su” of a
penicillin-G–treated group A Streptococcus pyogenes and possesses
cell regulatory activity.12–14 It leads to an elevation of many soluble cy-
tokines, such as interferon-γ, interleukin 1 and interleukin 2, tumor ne-
crosis factor, and activates neutrophils, macrophages, natural killer
cells, and T cells.14–16 The sclerosing effect seems to be related to its
immunomodulatory activity. It was shown that OK-432 induces an
inflammatory reaction, as seen in a bacterial infection and that it addition-
ally causes regression by inducing specific apoptosis of lymphatic
endothelium.17–19 The agent has been used to treat congenital lymphatic
malformations with several reports of promising results.12,20 Some au-
thors recommend OK-432 as the first-line therapy in the treatment of
lymphatic malformations.12,21 It has also been shown to prevent and re-
duce postsurgical fluid accumulation in extended latissimus dorsi flap do-
nor sites with only minor adverse effects such as fever, erythema,
paraesthesia, and swelling, which usually disappear within 4 days after in-
tervention.22 OK-432 has been used for the treatment of lymphoceles in
the past, but studies are limited to case reports and case series.23,24
The purpose of this retrospective cohort study was to compare
the outcome of ST with OK-432 versus RA for the treatment of
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symptomatic LF after lymphadenectomy or lymph node biopsy in pa-
tients with metastatic melanoma.
MATERIALS AND METHODS
Approval to conduct this retrospective clinical study was ob-
tained by the local institutional review board (KEK BASEC-Nb.
2016-01133) in 2016. An amendment to the protocol allowed for re-
cruitment of cases in 2017.
Inclusion and Exclusion Criteria
For the purpose of this study, all male and female patients
(>18 years old) who underwent lymph node dissection or diagnostic
lymph node biopsy for metastatic melanoma with postoperative LF be-
tween January 2013 and August 2017 were included into this analysis.
Lymphocele formation was treated either by RA or STwith OK-432.
The latter was applied since the beginning of the study period, if 3 per-
cutaneous fluid aspirations failed to control the refilling of the
lymphocele. Patients being under immunosuppressive therapy (eg,
due to solid organ transplantation), preexisting infection at the surgical
site, or ongoing intravenous drug abuse were excluded from this analy-
sis. Patients with surgical biopsies before dissection as well as patients
with prior detected distant metastasis were excluded. Patients with
preexisting severe skin disease such as atopic dermatitis, acne inversa,
and other lymphocutaneous fistula, and concomitant treatment with an-
tibiotics or chemotherapy were also excluded.
Patients
A systematic query of all operation reports and clinical follow-
up data between January 2013 and August 2017 identified a total of
40 patients whomet the inclusion criteria and had no reasons for exclusion.
Thus, 18 women and 22 men (mean ± SD age, 61 ± 13 years) were in-
cluded into this analysis. During the study period, the institutional treat-
ment algorithm has changed from RA alone to STwith OK-432. Of the
total cohort, 20 patients were treated with RA alone, and n = 20 patients
were treated with ST. All clinical data were derived from the electronic
patient files. Patient demographics including risk factors for LF are
displayed in Table 1. Patients treated with STwere significantly older;
otherwise, patient characteristics of both cohorts were comparable.
Surgery
Patients in both cohorts received level I/II axillary or inguinal
lymph node dissection or lymph node biopsy in a standard fashion at
our institution: dissection by electrocauterization was the preferred
method. Lymphatic vessels that could be identified during lymph node
dissection were ligated, clipped, or closed by electrocauterization ac-
cording to surgeon's preference, as there is neither a standardized
technique nor a scientific consensus on this issue so far. Muscle
flaps to reduce dead space formation are not performed because of
surgeon's preference and because there is also no scientific consen-
sus on its benefit so far. Wound closure was performed by subcuta-
neous absorbable sutures combined with absorbable intracutaneous
running sutures. Intraoperatively, a standard 12-gauge suction drain
was placed, which was removed the latest by the 10th postoperative
day to achieve wound healing. After lymph node biopsy, no suction
drain was placed. After removal of the drain, patients were followed
up in the outpatient clinic for wound healing.
Percutaneous Repetitive Fluid Aspiration
Twenty patients with symptomatic LF were followed up and
treated according to the new institutional algorithm in intervals of
7 days. These patients were treated with RA for a maximum of 3 times.
Ultrasound guidance is generally not performed at the authors' institu-
tion, and aspirated volumes were unfortunately not documented. In case
of persistent lymphocele, patients were sent to the interventional radiology
department for ST. In case of wound dehiscence or a surgical site infection
(SSI), surgical revision including microscopic lymphatic vessel ligature or
lymphovenous anastomosis was performed, if feasible.
ST With OK-432
All patients underwent ultrasound of the lymphocele before the
first ST to determine the extent and volume of the lymphocele. Patients
were then prepped and draped in a sterile fashion. Under sonographic
guidance, an 8.5F drain (Multipurpose Drainage Catheter; Cook Med-
ical, Bloomington, Indiana) was placed via trocar technique. Additional
side holes were made before placement to ensure that the entire collec-
tion is drained sufficiently. The locking loop was formed and the cath-
eter fixed at the skin level with sutures. A stopcock was attached to the
drain. After catheter placement, the entire fluid was aspirated, and the
amount of fluid was noted. OK-432was dissolved in 1mL of sterile dis-
tilled water and further diluted with 9 mL of saline (0.9%) in a 10-mL
syringe. This was done to overcome the dead space of the catheter.
The 10-mL preparation of OK-432 was then injected through the drain
into the lymphocele, and the stopcock was closed. At the first ST ses-
sion, patients were monitored in the interventional unit for 1 hour. Be-
fore discharge, OK-432 was completely aspirated because of patient
comfort. All patients received a calibrated drain bag. Patients were
asked to connect the drain with the drain bag once a day and to note
the amount of fluid. Moreover, patients were informed about potential
adverse effects of OK-432, which are fever not higher than 38°C, skin
redness over the lymphocele, and flulike symptoms (headache, abnor-
mal fatigue). All patients were followed up at an interval of 7 days at
the interventional radiology outpatient clinic. At every follow-up visit,
an ultrasound of the lymphocele was performed. Depending on the av-
erage fluid drainage per day and sonographic appearance of the
lymphocele, another STwas performed. Effective ST shows a change
in the sonographic appearance of the lymphocele with an increase of
hyperechogenic septa that finally end up in a honeycomb-like appear-
ance (Fig. 1). In case of complete cessation of fluid drainage, the drain
TABLE 1. Patient Characteristics of Patients Treated With RA or
ST With OK-432
ST OK-432 (n = 20) RA (n = 20) P*




BMI, kg/m2† 26 ± 4 26 ± 6 0.91
Smoking‡ 3 7 0.06
Diabetes‡ 1 2 0.31
Axillary‡ 9 5 0.19
Lymph node dissection 8 5
Lymph node biopsy 1
Inguinal‡ 11 15 0.19
Lymph node dissection 9 13
Lymph node biopsy 2 2
Bold data indicates statistically significant.
*A P value of <0.05 is considered significant.
†Data are represented as mean ± SD and (range).
‡Data are represented as number of patients.
BMI, body mass index; Smoking, positive when actual or any smoking in the
past years ≥10 pack-years.
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was removed. The catheter entry site at the skin was left open. Proce-
dure and doses were standardized across all patients.
OK-432 had been initially obtained for the treatment of congen-
ital cystic lymphatic malformations by the authors' predecessors. How-
ever, because the institution is not a children's hospital, the agent was
readily available to be used for the treatment of chronic postoperative
lymphocele. Incidentally, shortly after the end of the study period, in
October 2018, Chugai Pharmaceuticals Co Ltd officially announced
that they were suspending the development of OK-432. OK-432 is no
longer available.
Primary and Secondary Outcomes
Primary end points were as follows: overall treatment duration,
number of treatment sessions, and the clinical success in both cohorts.
Clinical success is defined as no recurrence of the lymphocele or com-
plete cessation of fluid production measured by the drain. Overall dura-
tion of treatment started after a total of 3 percutaneous aspirations.
Secondary end points were as follows: SSI rate, need for additional
antibiotic treatment, wound healing disorders, and the need for revision
surgery. In the subgroup that received ST with OK 432, adverse side
effects were analyzed. Moreover, development of lymphedemawas noted.
Statistical Analysis
Statistical analysis was performed by using commercially avail-
able software (IBM, SPSS statistics, Version 23; SPSS Inc, Chicago,
Illinois). Continuous variables are expressed as mean ± SD. Categorical
variables are expressed as frequencies or percentages. Results were
tested for normality using the Kolmogorov-Smirnov test. Normal dis-
tributed variables were compared by using the paired-samples t test. A
P value of less than 0.05 was considered statistically significant. This
study was conducted according to the Strengthening the Reporting of
Observational Studies in Epidemiology guidelines.
RESULTS
Forty patients with recurrent LF after lymph node dissection for
melanoma treatment were included in this study. Twenty patients with
RA of lymphocele were assigned to the first cohort. The second cohort
consisted of 20 patients who underwent STwith OK-432 after 3 aspira-
tions failed to control the lymphocele. Patients who received STwere
significantly older; otherwise, patient characteristics of both cohorts
were comparable. Distribution of axillary and inguinal lymph node dis-
sections did not significantly differ in both cohorts (Table 1).
Primary End points
Overall, the mean treatment duration was significantly shorter in
the ST cohort than in the group that received RA only (9.4 ±1.2 vs
47.5 ± 31.9 days, P < 0.01; Fig. 2). As stated previously, duration of
treatment was counted after 3 RAs in each cohort. In the ST cohort,
the mean number of treatment sessions was 2.5 ± 1.2, which was signif-
icantly less than that in the RA cohort (4.1 ± 1.8, P < 0.01). The mean
number of ST sessions of axillary (2 ± 1 sessions) and inguinal
lymphoceles (3 ± 2 session) did not significantly differ (P > 0.2). Clinical
successes were n = 7/20 patients for RA and n = 19/20 patients for ST.
Secondary End Points
Surgical site infections were seen in 5 of 20 patients treated with
RA, whereas none of the patients who were treated with OK-432
FIGURE 1. A 74-year-old man with metastatic malign melanoma and with a large symptomatic lymphocele after inguinal lymph node
dissection. A, Ultrasound before the first ST shows a hypoechogenic collection (white arrow). B, Ultrasound after 2 ST with OK-432
displays multiple hyperechogenic septae (white arrow) but still some remnant collections (white arrowhead). C, After the third ST, the
lymphocele has a honeycomb-like aspect. No more fluid could be drained, and the drain was removed.
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developed SSI (P < 0.03; Fig. 3). Antibiotic therapy was mandatory in
5 patients in the RA cohort. No additional antibiotic therapy had to be
installed in the ST cohort. Wound healing disorders were seen in 13
of 20 patients treated with RA and in 1 of 20 patient who underwent
ST. Patients treated with ST had a significantly lower rate of revision
surgeries than did patients treated with RA (P < 0.01). Revision surgery
of 1 patient in the ST cohort was due to late wound dehiscence caused
by skin necrosis after epidermolysis, which was present already imme-
diately after the operation. Reasons for the high percentage of revision
surgeries in the RA cohort were infectious wound breakdown. In the ST
cohort, 5 patients had OK-432–related adverse effects (mild fever,
n = 2; localized erythema and swelling, n = 3). All of these adverse ef-
fects were temporary and resolved within 2 to 3 days without taking any
further actions. None of these patients presented to the emergency unit
or had to be hospitalized because of these effects. One patient
underwent percutaneous aspiration 8 times during a period of
3 months and developed lymphedema during the duration of treatment
with RA. No patient developed lymphedema over the course of ST
with OK-432.
DISCUSSION
Recurrent lymphocele after lymph node dissection or biopsy for
diagnostic and therapeutic reasons remains a frequent clinical problem.
Symptomatic LF can be expected in every second patient after lymph-
adenectomy.3 Postoperative treatment options are limited, and repeated
percutaneous aspiration is often the treatment of choice. However, RA
increases the risk of local infections and other complications that may
delay patient recovery and markedly add to patient discomfort. Given
the incidence and consequences of symptomatic lymphocele, there is
a demand for an effective method to treat LF.
Results of this retrospective, comparative cohort study demonstrate
that STusingOK-432 significantly shortens the overall treatment timewith
a significantly lower amount of outpatient visits compared with tradi-
tional repetitive fluid aspiration. Moreover, ST with OK-432 allows
for a further reduction in morbidity associated with LF. Surgical site in-
fections were not seen in patients treated with ST, which is probably re-
lated to the catheter that allowed for intermittent draining of lymphocele
cavity. The presence of a drain further decreases skin closure tension,
which allows for primary wound healing. One major advantage is that
the rate of revision surgery was significantly decreased using ST. In
19 of 20 patients who received STwith OK-432, treatment was success-
ful and no further therapy was necessary. Results presented in this study
show a significant effect of STwith OK-432 on frequency and overall
duration of treatment. Ethanolum absolutum, for example, is an inex-
pensive and readily available sclerosing agent. Because its application
can be painful, it sometimes has to be instilled at least under moderate
sedation. Only a few small-scale studies imply that weekly instillations
of ethanol are necessary to achieve complete resolution within
1 month.25,26 In a previous study, povidone iodine solution was instilled
2 to 3 times daily through a catheter into the cavity, increasing risk of
infection.26 Symptoms of iodine toxicity might occur and serum iodine
FIGURE 2. Comparison of mean duration of treatment (number of days after 3 RAs in both groups). *P < 0.05.
FIGURE 3. Number of SSI and revision surgeries in both groups. *P < 0.05.
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levels need to be monitored, as lethality has been reported after contin-
uous mediastinal irrigation with povidone iodine.27 Lesions healed
within 4 to 8 weeks after weekly application of tetracyclines, whereas
reported complications included severe burn sensation, reduced skin
mobility or tightness, and contour deformity.28 Preventive use of tetra-
cyclines may even increase the risk of chronic fluid accumulation.29 In
addition, tetracycline and polyvidone-iodine cannot be used in patients
with allergies to certain antibiotics or iodine. A cost analysis and patient
satisfaction survey was not included in this study. However, based on
the results of this study, we hypothesize that OK-432 most likely reduces
costs and patient discomfort as it decreases the number of revision surger-
ies and shortens overall treatment time compared with RA. Studies com-
paring different sclerotherapeutic agents in specific have to be conducted
to demonstrate significant supremacy of one agent over the other.
Regarding postinjection complications, OK-432 adverse effects
were minor and limited to mild fever and local erythema and swelling
in our patient collective. We did not conduct laboratory test, but none
of our patients presented emergently or had to be hospitalized because
of adverse effects of the treatment. We did not use OK-432 in immuno-
compromised patients because the course of adverse effects of OK-432
in immunocompromised patients is unknown and expected to be more
intense. Also, STwith OK-432 requires tissue adhesion, which is very
limited in an immunocompromised patient. In the literature, several
OK-432 injection adverse effects were reported in patients mainly
treated for lymphatic malformations. Erythema, discomfort, induration,
swelling at the injection site, and fever that resolved with paracetamol
and nonsteroidal anti-inflammatory drugs after 1 to 3 days are the most
often reported ones.30–32 In patients with head and neck lymphatic
malformations, elevated serum levels of IP-10, C-reactive protein, and
leukocyte indicated that OK-432 ST induces systemic immune re-
sponses in patients with LM.31However, all 17 patients in this study ex-
perienced only local tenderness, and most of them had fever related to
OK-432 ST. Only one patient developed a peritonsillar abscess at
16 days after the second OK-432 injection into his macrocystic lesion
in the floor of the mouth and submandibular space.31 Another study
about the treatment of head and neck lymphangiomas in 15 children re-
ported postinjection anemia that resolved only after concentrated red
blood cell transfusion in one child and only transitory increase of plate-
lets' concentration, with spontaneous resolution within 1 month in 6
other.32No electrolyte alteration was recorded in that study. We hypoth-
esize that its use for lymphatic malformations is more invasive.
There is also a potential risk of developing postinterventional
lymphedema, as OK-432 leads to specific apoptosis of lymph endothe-
lium and because of the localized inflammation to an adhesion of the
wound bed. We only followed up our patients until the lymphocele
was resolved. During that period, we did not see any lymphedema in
the ST cohort. One patient in the RA cohort developed lymphedema.
Lymphocele formation itself is a risk of developing lymphedema.33
Conclusively, further prospective wide-scale clinical studies and long-
term follow-ups are needed to clarify and prove its safe application
for recurrent lymphocele. In general, we strongly advise to inform pa-
tients about the risk of recurrent lymphocele and to educate all patients
who develop symptomatic lymphocele as to the anticipated course of
risks and treatment.
Based on our clinical experience, we developed an algorithm for
our clinic on how to approach recurrent lymphocele (Fig. 4). This algo-
rithm seemed to be useful and practical, although, among its several
components, effectiveness has to be proven yet.
If LF is present and wound healing is not compromised, we aspirate
the lymphocele amaximum of 3 times and refer the immunocompetent pa-
tient to STwith OK-432 if lymphocele is persistent. If wound healing is
compromised, the fistula is apparent, or an immunocompromised patient
already received 3 percutaneous aspirations, we perform revision surgery.
Depending on wound bed condition, we combine debridement with sec-
ondary wound closure or prepare the wound bed with negative pressure
therapy. Lymphatic microsurgery is another emerging treatment of option
for reconstructive surgeons. It was shown that inguinal lymphocele preven-
tion was possible by primarily indocyanine green mapping of wound bed
area.34 Refractory groin lymphocele was treated successfully by surround-
ing supermicrosurgical lymphaticovenous anastomosis.35,36 Before wound
closure, we routinely use indocyanine green to detect lymphatics, and if
suitable, we conduct lymphovenous or lympholymphatic anastomosis.
We ligate and clip lymphatics that are not suitable for microsurgical recon-
struction. If necessary, we perform musculocutaneous or muscle flaps to
FIGURE 4. Algorithm on how to approach chronic postoperative lymphocele.
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close the dead space or skin defect. If lymphocele persists after ST, we per-
form revision surgery. If lymphocele still persists after revision surgery and
the patient is immunocompetent, we performSTwithOK-432. In immuno-
compromised patients, alcohol may be used because OK-432 will not
cause an immune response and therefore will not be effective.
Limitations
Several limitations apply to this study. First, the study is of a ret-
rospective nature and long-term follow-up data are not available to this
study. The number of patients in both cohorts is limited and groups are
heterogeneous, as lymph node dissections and diagnostic lymph node
biopsies are very different surgeries, although most patients underwent
lymph node dissections. Furthermore, the impact of differences in tu-
mor stage has not been analyzed and included into this study. Because
of the lack of documentation, aspirated volumes and lymphocele sizes
could not be compared. In fact, the volume aspirated in each clinical en-
counter and the trend of decreasing volume will provide valuable data
and meaningful comparison. The effectiveness as well as complication
rate and adverse effects have to be tested and compared in larger ran-
domized patient cohorts and prospectively to further prove the efficacy
of OK-432.
CONCLUSION
Compared with RA, STwith OK-432 of symptomatic lymphoceles
after lymph node dissection shows a high clinical success with a signif-
icant reduction of the overall treatment time and number of outpatients
visit. Moreover, ST allows for a significant reduction in SSIs and
revision surgeries.
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